Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The LEADER trial enrolled patients with T2DM and high cardiovascular risk, defined as established CVD (81%) or age 60 years with at least one risk factor, and showed that liraglutide significantly reduced the incidence of 3-point major adverse cardiovascular events (MACE) (i.e., CV death, non-fatal myocardial infarction, non-fatal stroke) by 13% compared to placebo (HR 0.87
The science behind both is real
New England Journal of Medicine, 387(3), 205-216
Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
One of the innovative treatments we offer is the use of GLP-1 medications, such as Ozempic (semaglutide), which have recently gained widespread attention for their effectiveness in weight management and metabolic health
US$ 28.52
US$ 22.02
US$ 21.34
US$ 29.67
US$ 22.80
US$ 26.94
US$ 28.24
